Outcomes of vitrectomy, complete pan-retinal photocoagulation, and endoscopic cyclophotocoagulation surgery after anti-VEGF treatment in neovascular glaucoma
- AOPR Vol. 3, Issue 3, Pages: 112-118(2023)
- 作者机构：
1. ,Beijing,China,100853
2. ,Beijing,China
- 作者简介：
- 基金信息：
DOI：10.1016/j.aopr.2023.05.001
CLC：
扫 描 看 全 文
Jinglan Li, Siwenyue Zhang, Baoke Hou. Outcomes of vitrectomy, complete pan-retinal photocoagulation, and endoscopic cyclophotocoagulation surgery after anti-VEGF treatment in neovascular glaucoma. [J]. AOPR 3(3):112-118(2023)
Jinglan Li, Siwenyue Zhang, Baoke Hou. Outcomes of vitrectomy, complete pan-retinal photocoagulation, and endoscopic cyclophotocoagulation surgery after anti-VEGF treatment in neovascular glaucoma. [J]. AOPR 3(3):112-118(2023) DOI： 10.1016/j.aopr.2023.05.001.
摘要
Purpose,To establish a comprehensive treatment strategy and evaluate the efficacy of combination of anti-vascular endothelial growth factor (VEGF) injection, pars plana vitrectomy (PPV), endoscopic pan-retinal photocoagulation (PRP), and endoscopic cyclophotocoagulation (ECP) surgery for neovascular glaucoma (NVG) patients.,Methods,This retrospective study included 30 patients (30 eyes) who were suffering from NVG and treated with PPV & PRP & ECP (ECP group, 16 eyes), or Ahmed glaucoma valve implantation (Ahmed group, 14 eyes). The intraocular pressure (IOP), number of postoperative anti-glaucoma medications, best-corrected visual acuity (BCVA), successful rate of surgery, and postoperative complications were recorded and statistically analyzed at the time points of preoperative, 1-day, 1-month, 3-months, 6-months, and 12-months after operation.,Results,An obvious reduction in IOP and number of postoperative anti-glaucoma medications were observed in both the ECP group and Ahmed group after operation (,P, ,<, 0.05), and the ECP group showed a significantly lower IOP compared to the Ahmed group at the 6-months (,P, = 0.014) and 12-months (,P, = 0.047) postoperative time points, while there was no significant difference of medication number between the two groups except for 1-day after surgery. The BCVA showed no marked difference between the two groups preoperatively and postoperatively (,P, ,>, 0.05), while it was significantly improved in ECP group at 3-months (,P, = 0.001), 6-months (,P, = 0.004), and 12-months (,P, = 0.010) time points comparing with preoperative BCVA. The surgical success rates in ECP group were also slightly higher than Ahmed group. And the complications after operation showed no marked differences.,Conclusions,The comprehensive treatment of PPV, endoscopic PRP, and ECP surgery for NVG patients after anti-VEGF injection can control IOP effectively and be friendly to patients’ BCVA without obvious serious complications throughout a 12-months follow-up period.
Abstract
Purpose,To establish a comprehensive treatment strategy and evaluate the efficacy of combination of anti-vascular endothelial growth factor (VEGF) injection, pars plana vitrectomy (PPV), endoscopic pan-retinal photocoagulation (PRP), and endoscopic cyclophotocoagulation (ECP) surgery for neovascular glaucoma (NVG) patients.,Methods,This retrospective study included 30 patients (30 eyes) who were suffering from NVG and treated with PPV & PRP & ECP (ECP group, 16 eyes), or Ahmed glaucoma valve implantation (Ahmed group, 14 eyes). The intraocular pressure (IOP), number of postoperative anti-glaucoma medications, best-corrected visual acuity (BCVA), successful rate of surgery, and postoperative complications were recorded and statistically analyzed at the time points of preoperative, 1-day, 1-month, 3-months, 6-months, and 12-months after operation.,Results,An obvious reduction in IOP and number of postoperative anti-glaucoma medications were observed in both the ECP group and Ahmed group after operation (,P, ,<, 0.05), and the ECP group showed a significantly lower IOP compared to the Ahmed group at the 6-months (,P, = 0.014) and 12-months (,P, = 0.047) postoperative time points, while there was no significant difference of medication number between the two groups except for 1-day after surgery. The BCVA showed no marked difference between the two groups preoperatively and postoperatively (,P, ,>, 0.05), while it was significantly improved in ECP group at 3-months (,P, = 0.001), 6-months (,P, = 0.004), and 12-months (,P, = 0.010) time points comparing with preoperative BCVA. The surgical success rates in ECP group were also slightly higher than Ahmed group. And the complications after operation showed no marked differences.,Conclusions,The comprehensive treatment of PPV, endoscopic PRP, and ECP surgery for NVG patients after anti-VEGF injection can control IOP effectively and be friendly to patients’ BCVA without obvious serious complications throughout a 12-months follow-up period.
关键词
Keywords
Neovascular glaucomaEndoscopic cyclophotocoagulationPars plana vitrectomyPan-retinal photocoagulationAnti-VEGF
references
1 S Senthil, T Dada, T Das, et al.Neovascular glaucoma - a review Indian J Ophthalmol, 69 (3) (2021), pp. 525-534, 10.4103/ijo.IJO_1591_20
2 S Jabbehdari, G Yazdanpanah, LB Cantor, AR HajrasoulihaA narrative review on the association of high intraocular pressure and glaucoma in patients with retinal vein occlusion Ann Transl Med, 10 (19) (2022), p. 1072, 10.21037/atm-22-2730
3 D Calugaru, M CalugaruEtiology, pathogenesis, and diagnosis of neovascular glaucoma Int J Ophthalmol, 15 (6) (2022), pp. 1005-1010, 10.18240/ijo.2022.06.20
4 R Terao, R Fujino, T AhmedRisk factors and treatment strategy for retinal vascular occlusive diseases J Clin Med, 11 (21) (2022), 10.3390/jcm11216340
5 R Greslechner, H HelbigSecondary glaucoma in the context of retinal disease Klin Monbl Augenheilkd, 239 (9) (2022), pp. 1111-1118, 10.1055/a-1797-5188
6 FHP Lai, EWN Wong, WC Lam, et al.Endoscopic vitreoretinal surgery: review of current applications and future trends Surv Ophthalmol, 66 (2) (2021), pp. 198-212, 10.1016/j.survophthal.2020.11.004
7 A Katsanos, K Gorgoli, DG Mikropoulos, et al.Assessing the role of ranibizumab in improving the outcome of glaucoma filtering surgery and neovascular glaucoma Expet Opin Biol Ther, 18 (6) (2018), pp. 719-724, 10.1080/14712598.2018.1479395
8 AA ArefCurrent management of glaucoma and vascular occlusive disease Curr Opin Ophthalmol, 27 (2) (2016), pp. 140-145, 10.1097/ICU.0000000000000239
9 European glaucoma society terminology and guidelines for glaucoma, 5th edition Br J Ophthalmol, 105 (Suppl 1) (2021), pp. 1-169, 10.1136/bjophthalmol-2021-egsguidelines
10 JA Sivak-Callcott, DM O’Day, JD Gass, JC TsaiEvidence-based recommendations for the diagnosis and treatment of neovascular glaucoma Ophthalmology, 108 (10) (2001), pp. 1767-1776, 10.1016/s0161-6420(01)00775-8 quiz77, 800
11 YK Kang, JP Shin, DW KimLong-term surgical outcomes of Ahmed valve implantation in refractory glaucoma according to the type of glaucoma BMC Ophthalmol, 22 (1) (2022), p. 270, 10.1186/s12886-022-02493-w
12 C Bernal-Morales, M Dotti-Boada, A Olate-Perez, MJ Navarro-Angulo, L Pelegrin, M Figueras-RocaSimultaneous pars plana vitrectomy, panretinal photocoagulation, cryotherapy, and Ahmed valve implantation for neovascular glaucoma Int J Ophthalmol, 14 (9) (2021), pp. 1396-1401, 10.18240/ijo.2021.09.15
13 Y Murakami, H Akil, J Chahal, et al.Endoscopic cyclophotocoagulation versus second glaucoma drainage device after prior aqueous tube shunt surgery Clin Exp Ophthalmol, 45 (3) (2017), pp. 241-246, 10.1111/ceo.12828
14 FE Lima, L Magacho, DM Carvalho, R Susanna Jr., MP AvilaA prospective, comparative study between endoscopic cyclophotocoagulation and the Ahmed drainage implant in refractory glaucoma J Glaucoma, 13 (3) (2004), pp. 233-237, 10.1097/00061198-200406000-00011
15 P Lin, Q Zhao, J He, W Fan, W He, M LaiComparisons of the short-term effectiveness and safety of surgical treatment for neovascular glaucoma: a systematic review and network meta-analysis BMJ Open, 12 (5) (2022), Article e051794, 10.1136/bmjopen-2021-051794
16 A Cohen, SH Wong, S Patel, JC TsaiEndoscopic cyclophotocoagulation for the treatment of glaucoma Surv Ophthalmol, 62 (3) (2017), pp. 357-365, 10.1016/j.survophthal.2016.09.004
17 Y Yang, J Zhong, Z Dun, XA Liu, M YuComparison of efficacy between endoscopic cyclophotocoagulation and alternative surgeries in refractory glaucoma: a meta-analysis Medicine (Baltim), 94 (39) (2015), Article e1651, 10.1097/MD.0000000000001651
18 HB Hwang, JW Han, HB Yim, NY LeeBeneficial effects of adjuvant intravitreal bevacizumab injection on outcomes of Ahmed glaucoma valve implantation in patients with neovascular glaucoma: systematic literature review J Ocul Pharmacol Therapeut, 31 (4) (2015), pp. 198-203, 10.1089/jop.2014.0108
19 L Bai, Y Wang, X Liu, et al.The optimization of an anti-VEGF therapeutic regimen for neovascular glaucoma Front Med, 8 (2021), Article 766032, 10.3389/fmed.2021.766032
20 Y He, B He, Z Ji, et al.Modified trabeculectomy versus glaucoma drainage implant surgery: a retrospective comparative study for refractory glaucoma treatment Oxid Med Cell Longev, 2022 (2022), Article 3050007, 10.1155/2022/3050007
21 A Simha, A Braganza, L Abraham, P Samuel, K LindsleyAnti-vascular endothelial growth factor for neovascular glaucoma Cochrane Database Syst Rev (10) (2013), p. CD007920, 10.1002/14651858.CD007920.pub2
22 M Kim, C Lee, R Payne, BY Yue, JH Chang, H YingAngiogenesis in glaucoma filtration surgery and neovascular glaucoma: a review Surv Ophthalmol, 60 (6) (2015), pp. 524-535, 10.1016/j.survophthal.2015.04.003
23 LB Lindsell, MM Lai, HF FineCurrent concepts in managing retinal vein occlusion in young patients Ophthalmic Surg Lasers Imaging Retina, 46 (7) (2015), pp. 695-701, 10.3928/23258160-20150730-02
24 KV Marra, S Wagley, A Omar, et al.Case-matched comparison of vitrectomy, peripheral retinal endolaser, and endocyclophotocoagulation versus standard care in neovascular glaucoma Retina, 35 (6) (2015), pp. 1072-1083, 10.1097/IAE.0000000000000449
25 YS Cheng, SH Lin, CJ ChangCombined Endoscope assisted Procedures (CEaP) as a complete treatment for neovascular glaucoma PLoS One, 15 (6) (2020), Article e0234798, 10.1371/journal.pone.0234798
26 IR Gorovoy, AW EllerEndocyclophotocoagulation as an adjuvant to vitreoretinal surgery in cases with concomitant glaucoma Ophthalmic Surg Lasers Imaging Retina, 44 (3) (2013), pp. 243-247, 10.3928/23258160-20130503-06
27 D Doganay, S Doganay, C CankayaPars plana vitrectomy combined with pan-retinal photocoagulation, Ahmed glaucoma valve implantation, and/or phacoemulsification for complicated neovascular glaucoma treatment Arq Bras Oftalmol (2022), 10.5935/0004-2749.2021-0187
28 EC Bowden, A Choudhury, SJ Gedde, et al.Risk factors for failure of tube shunt surgery: a pooled data analysis Am J Ophthalmol, 240 (2022), pp. 217-224, 10.1016/j.ajo.2022.02.027
29 V Andres-Guerrero, L Perucho-Gonzalez, J Garcia-Feijoo, et al.Current perspectives on the use of anti-VEGF drugs as adjuvant therapy in glaucoma Adv Ther, 34 (2) (2017), pp. 378-395, 10.1007/s12325-016-0461-z
30 JM Smith, DH SteelAnti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy Cochrane Database Syst Rev (8) (2015), p. CD008214, 10.1002/14651858.CD008214.pub3
0
Views
0
下载量
0
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.